{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:04:38Z","timestamp":1793408678864,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004024","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,1,23]],"date-time":"2008-01-23T00:00:00Z","timestamp":1201046400000}}],"reference-count":136,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004024.pub2","type":"journal-article","created":{"date-parts":[[2008,2,5]],"date-time":"2008-02-05T20:11:33Z","timestamp":1202242293000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults"],"prefix":"10.1002","volume":"2011","author":[{"given":"Alexander","family":"Greb","sequence":"first","affiliation":[{"name":"Carl Schurz Strasse 8 Cologne Germany 50935"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bohlius","sequence":"additional","affiliation":[{"name":"University of Bern; Institute of Social and Preventive Medicine; Bern Switzerland 3012"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schiefer","sequence":"additional","affiliation":[{"name":"University Hospital Ulm; Department of Internal Medicine II; Steinhoevelweg 9 Ulm Germany D-89070"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Schwarzer","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg; German Cochrane Centre; Stefan-Meier-Str. 26 Freiburg Germany D-79104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Schulz","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"key":"10.1002\/14651858.CD004024.pub2-BIB0001|cit1","unstructured":"De Souza CA Baldissera RC Simoes BP Maiolino A Moraes AAJG Ruiz MA Unselected High-Risk IPI NHL Presented a High Early Mortality Rate in a prospective Randomized Study Comparing Conventional Chemotherapy and High-Dose Escalation Followed by Autologous Bone Marrow Transplantation Blood 2001 391b"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0002|cit2","unstructured":"Gianni AM Bregni M Siena S Brambilla C Di Nicola M Lombardi F Gandola L Tarella C Pileri A Stern A Valagussa P Bonadonna G Is high-dose better than standard dose chemotherapy as initial treatment of poor risk large cell lymphomas? A critical analysis from available randomized trials [abstract] Annals of Oncology 1996 12 19"},{"issue":"18","key":"10.1002\/14651858.CD004024.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","article-title":"High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma","volume":"336","author":"Gianni","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD004024.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0006|cit5","unstructured":"Gisselbrecht C Lepage E Morel P Lederlin P Coiffier B Tilly H Bosly A Gabarre J Briere J Fillet G Molina T Reyes F Failure of early autologous stem cell transplantation in poor risk patients with aggressive lymphoma: updated results of the LNH93-3 study [abstract] Annals of Hematology 2001 B157 26"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0005|cit6","unstructured":"Gisselbrecht C Lepage E Morel P Lederlin P Coiffier B Tilly H Bosly A Gabarre J Briere J Fillet G Molina T Reyes F GELA Intensified induction phase including autologous peripheal stem cell transplantation does not improve response rate and survival in lymphoma with at least 2 adverse prognostic factors when compared to ACVD regimen [abstract] Blood 1996 120a 5"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0007|cit7","unstructured":"Gisselbrecht C Lepage E Morel P Lederlin P Coiffier B Tilly H Short and intensified treatment with autologous stem cell transplantation (ASCT) versus ACVB regimen in poor prognosis aggressive lymphoma. LNH93-3 protocol [abstract] Bone Marrow Transplantation 1997 S153 3814"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0008|cit8","unstructured":"Reyes F Lepage E Morel P Lederlin P Coiffier B Tilly H Bosly A Gabarre J Briere J Fillet G Molina T Gisselbrecht C GELA Failure of first line inductive high-dose chemotherapy in poor risk patients with aggressive lymphomas: updated results of the randomized LNH93-3 study [abstract] Blood 1997 594a 4"},{"issue":"3","key":"10.1002\/14651858.CD004024.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.1997.15.3.1131","article-title":"Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Haioun","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0010|cit10","unstructured":"Haioun C Lepage E Gisselbrecht C Bastion Y Doyen C Plantier I Schlaifer D Tilly H Deconnick E Bordessoule D Gaulard P Reyes F Autologous transplantation versus conventional salvage therapy in aggressive non-Hodgkin's lymphoma (NHL) partially responding to first line chemotherapy. A study of 96 patients enrolled in the LNH87-2 protocol [abstract] Blood 1995 211a 15"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0012|cit11","unstructured":"Haioun C Lepage E Gisselbrecht C Coiffier B Bosly A Dupriez B Autologous bone marrow transplantation (AMBT) versus sequential chemotherapy for aggressive non Hodgkin's lymphoma (NHL) in first complete remission (CR): a study of 541 patients (LNH87-2 protocol) [abstract] Annals of Oncology 1996 24 3988"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0011|cit12","unstructured":"Haioun C Lepage E Gisselbrecht C Coiffier B Bosly A Dupriez B Nouvel C Tilly H Lederlin P Biron P Briere J Gaulard P Reyes F Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy for aggressive non-Hodgkin's lymphoma (NHL) in first complete remission (CR): A study of 542 patients (LNH87-2 protocol) [abstract] Blood 1995 457a 16"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0013|cit13","unstructured":"Haioun C Lepage E Gisselbrecht C Coiffier B Bosly A Tilly H Morel P Nouvel C Herbrecht R D'Agay MF Gaulard P Reyes F GELA Comparison of autologous bone marrow transplantation (ABMT) with sequential chemotherapy for aggressive non-Hodgkin's lymphoma (NHL) in first complete remission [abstract] Blood 1993 87a 35"},{"issue":"12","key":"10.1002\/14651858.CD004024.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.1994.12.12.2543","article-title":"Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.","volume":"12","author":"Haioun","year":"1994","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Haioun C Lepage E Gisselbrecht C Salles G Coiffier B Brice P Bosly A Morel P Nouvel C Tilly H Lederlin P Sebban F Briere J Gaulard P Reyes F Survival benefit of high dose therapy over sequential chemotherapy in poor risk aggressive non-hodgkin's lymphoma. Final analysis of the prospective LNH87-2 protocol. A GELA study [abstract] Blood 1999 610a 6","DOI":"10.1200\/JCO.2000.18.16.3025"},{"issue":"16","key":"10.1002\/14651858.CD004024.pub2-BIB0016|cit16","first-page":"3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0017|cit17","unstructured":"Haioun C Lepage E Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy for aggressive non Hodgkin's lymphoma (NHL) in first complete remission (CR): a study of 542 patients. Bone Marrow Transplantation 1996 S144"},{"issue":"12","key":"10.1002\/14651858.CD004024.pub2-BIB0018|cit18","first-page":"3687","article-title":"Quality of life adjusted (Q-Twist) survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission","volume":"95","author":"Mounier","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0019|cit19","unstructured":"Mounier N Haioun C Sebban F Morel P Gisselbrecht C Lepage E GELA Quality of life adjusted (Q-Twist) survival analysis of autologous bone marrow transplantation for aggressive lymphoma (NHL) patients in first complete remission [abstract] Blood 1998 370b 7"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0020|cit20","unstructured":"Mounier N Haioun C Sebban F Morel P Reyes F Gisselbrecht C Lepage E GELA Q-Twist analysis of high dose therapy with autologous transplantation for aggressive NHL patients in first complete remission [abstract] Bone Marrow Transplantation 1999 S167 34"},{"issue":"16","key":"10.1002\/14651858.CD004024.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0022|cit22","unstructured":"Intragumtornchai T Prayoonwiwat P Numbenjapon T O'Charoen R Assawametha N Swasdikul D Up-front high-dose therapy and autologous peripheral blood progenitor cell transplantation versus standard chop chemotherapy in poor prognosis aggressive non-Hodgkin's lymphoma: A preliminary report [abstract] Annals of Oncology 1999 79 3525"},{"issue":"3","key":"10.1002\/14651858.CD004024.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3816\/CLM.2000.n.018","article-title":"CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma","volume":"1","author":"Intragumtornchai","year":"2000","journal-title":"Clinical Lymphoma"},{"issue":"22","key":"10.1002\/14651858.CD004024.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1200\/JCO.2002.07.075","article-title":"Randomized study to evaluate the use of high-dose therapy as part of primary treatment for \"aggressive\" lymphoma","volume":"20","author":"Kaiser","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD004024.pub2-BIB0025|cit25","first-page":"611a","article-title":"High dose therapy with autologous stem cell transplantation in aggressive NHL: results of a randomized multicenter study [abstract]","volume":"94","author":"Kaiser","year":"1999","journal-title":"Blood"},{"issue":"Suppl","key":"10.1002\/14651858.CD004024.pub2-BIB0028|cit26","first-page":"S177","article-title":"High dose chemotherapy with autologous stem cell transplantation in high grade NHL: first analysis of a randomized multicenter study [abstract]","volume":"21","author":"Kaiser","year":"1998","journal-title":"Bone Marrow Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004024.pub2-BIB0029|cit27","first-page":"B157","article-title":"High dose therapy with autologous stem cell transplantation in aggressive NHL: results of a randomized multicenter study [abstract]","volume":"80","author":"Kaiser","year":"2001","journal-title":"Annals of Hematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004024.pub2-BIB0030|cit28","first-page":"S159","article-title":"High dose therapy with autologous stem cell transplantation in aggressive NHL: two years results of a randomized study [abstract]","volume":"23","author":"Kaiser","year":"1999","journal-title":"Bone Marrow Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004024.pub2-BIB0026|cit29","first-page":"76","article-title":"High dose chemotherapy with autologous stem cell transplantation in aggressive NHL: Analysis of a randomized multicenter study [abstract]","volume":"10","author":"Kaiser","year":"1999","journal-title":"Annals of Oncology"},{"issue":"Suppl II","key":"10.1002\/14651858.CD004024.pub2-BIB0027|cit30","first-page":"S11","article-title":"High dose chemotherapy with autologous stem cell transplantation in high grade NHL: results of a randomized multicenter study [abstract]","volume":"77","author":"Kaiser","year":"1998","journal-title":"Annals of Hematology"},{"issue":"1","key":"10.1002\/14651858.CD004024.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jnci\/93.1.22","article-title":"Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study","volume":"93","author":"Kluin-Nelemans","year":"2001","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0032|cit32","unstructured":"Kluin-Nelemans JC Zagonel V Anastasopoulou A Bron D Roozendaal K Noordijk EM Musson H Teodorovic I Maes B Carbone A Carde P Thomas J EORTC Lymphoma Group Final analysis of the EORTC 20901 study: consolidation autologous stem cell transplantation is not better than standard CHVmP\/BV chemotherapy alone for agressive non-Hodgkin's lymphoma [abstract] Annals of Hematology 2001 B156 29"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0033|cit33","unstructured":"Kluin-Nelemans JC Zagonel V Thomas J Teodorovic I Anastasopoulou A Bron D Carde P Consolidation ABMT after standard chemotherapy vs CHVmP\/BV alone for primary intermediate and high grade NHL: a randomized phase III EORTC study [abstract] Proceedings of the American Society of Clinical Oncology 1999 2a 30"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0034|cit34","unstructured":"Kluin-Nelemans JC Zagonel V Thomas J Teodorovic I Anastasopoulou A Bron D Carde P Consolidation ABMT after standard chemotherapy vs CHVmP\/BV alone for primary, intermediate and high grade NHL. A randomized phase III EORTC Study [abstract] Annals of Oncology 1999 24 20"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0035|cit35","unstructured":"Moser E Noordijk EM Glabbeke MV Theodorovic I Wolf-Peeters CD Carde P Long-term efficacy of the CHVmP\/BV regimen used for aggressive advanced non Hodgkin's lymphoma (NHL) across 3 randomized EORTC-trials. Proceedings of the American Society of Clinical Oncology 2003 Abstract No 2381"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD004024.pub2-BIB0036|cit36","first-page":"234a","article-title":"Autologous bone marrow transplantation (ABMT) vs DHAP in aggressive non-Hodgkin's lymphomas (NHL) partially responding to first-line chemotherapy [abstract]","volume":"84","author":"Gherlinzoni","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD004024.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1996.14.2.534","article-title":"High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study","volume":"14","author":"Martelli","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004024.pub2-BIB0038|cit38","first-page":"S160","article-title":"Chemotherapy in aggressive NHL with partial response to front line chemotherapy: Long term results of a randomized Italian Multicenter study [abstract]","volume":"23","author":"Martelli","year":"1999","journal-title":"Bone Marrow Transplantation"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD004024.pub2-BIB0039|cit39","first-page":"157a","article-title":"ABMT vs DHAP in residual disease following third generation regimens for aggressive non-Hodgkin's lymphomas [abstract]","volume":"80","author":"Tura","year":"1992","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0040|cit40","first-page":"144","article-title":"ABMT versus DHAP for aggressive non-Hodgkin's lymphoma patients in clinical partial response after third generation regimens: an Italian multicentric study [abstract]","volume":"13","author":"Vignetti","year":"1994","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0042|cit41","unstructured":"Gherlinzoni F Early autologous stem cell transplantation versus conventional first-line chemotherapy in high-risk aggressive non-hodgkin's lymphomas (NHL): an Italian multicenter randomized trial [abstract] Blood 1998 726a 3"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0041|cit42","unstructured":"Gherlinzoni F Martelli M Tura S Early autologous stem cell transplantation (ASCT) versus conventional first-line chemotherapy in high-risk aggressive non-hodgkin's lymphomas (NHL): an Italian multicentre randomized trial [abstract] Blood 2000 481a 2"},{"issue":"7","key":"10.1002\/14651858.CD004024.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.2003.01.117","article-title":"Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line Therapy in High-Risk, Aggressive Non-Hodgkin's Lymphoma: An Italian Multicenter Randomized Trial","volume":"21","author":"Martelli","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0044|cit44","unstructured":"Martelli M Gherlinzoni F Zinzani PL Meloni G Cantonetti M Storti S Early autologous stem cell transplantation as first-line therapy in poor prognosis non Hodgkin's lymphoma (NHL): An Italian randomized trial [abstract] Annals of Oncology 1999 78 3548"},{"issue":"4","key":"10.1002\/14651858.CD004024.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2141.2000.02098.x","article-title":"Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial","volume":"109","author":"Deconinck","year":"2000","journal-title":"British Journal of Haematology"},{"issue":"13","key":"10.1002\/14651858.CD004024.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","article-title":"Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support","volume":"350","author":"Milpied","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0047|cit47","unstructured":"Milpied N Deconnick E Colombat P Foussard C Desablens B Delwail V Berthou C Gressin R Lamy T Jaubert J Cassasus P Le Tortorec S Le Maignan C Maisonneuve H Ramee JF Lemevel A Jardel H Moreau P Harousseau JL Frontline high dose chemotherapy with autologous stem cell transplantation is not superior to CHOP regimen for adult patients with non IPI high risk intermediate or high grade NHL: Results of a randomized trial by the GOELAMS [abstract] Annals of Oncology 1999 77 23"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0048|cit48","unstructured":"Milpied N Deconnick E Colombat P Ifrah N Delwail V Berthou C Gressin R Lamy T Jaubert J Cassasus P Le Maignan C Maisonneuve H Ramee JF Lemevel A Jardel H Desablens B Harousseau JL Frontline high dose chemotherapy (HDC) with autologous stem cell transplantation vs standard CHOP regimen for patients (<60yo) with non IPI high risk intermediate or high grade lymphomas (NHL). Final results of a randomized trial [abstract] Annals of Oncology 2002 28 22"},{"issue":"11 Part 1","key":"10.1002\/14651858.CD004024.pub2-BIB0049|cit49","first-page":"180a","article-title":"Frontline high dose chemotherapy (HDC) with autologous stem cell transplantation vs standard CHOP regimen for patients (pts) (<or = 60yo) with non IPI high risk intermediate or high grade lymphomas (NHL). Final results of a randomized trial by the GOELAMS [abstract]","volume":"100","author":"Milpied","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0050|cit50","unstructured":"Milpied N Deconnick E Colombat P Ifrah N Delwail V Berthou C Gressin R Lamy T Jaubert J Cassasus P Le Maignan C Maisonneuve H Ramee JF Lemevel A Jardel H Moreau P Harousseau JL GOELAMS Frontline high-dose chemotherapy (HDC) with autologous stem cell transplantation compared to standard CHOP regimen: a randomized trial for adult patients with non IPI high-risk intermediate or high grade lymphomas (NHL) [abstract] Blood 1999 610a 9"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0051|cit51","unstructured":"Milpied N Deconnick E Colombat P Ifrah N Delwail V Berthou C Gressin R Lamy T Jaubert J Cassasus P Le Maignan C Maisonneuve H Ramee JF Lemevel A Jardel H Moreau P Harousseau JL GOELAMS Frontline high-dose chemotherapy with autologous stem cell transplantation compared to standard CHOP regimen: a randomised trial for adult patients (< 60 y) with non IPI high risk intermediate or high grade lymphomas [abstract] Hematology Journal 2000 66 42"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0052|cit52","unstructured":"Rodriguez MA van Besien K Hagemeister FB Giralt S McLaughlin P Gajewski JL Romaguera J Khouri IF Younes A Cabanillas FC Champlin R Randomized comparison of frontline alternating chemotherapy (ATT) versus brief induction followed by autologous stem cell transplantation (ASCT) for aggressive lymphomas Blood 2003"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0053|cit53","unstructured":"Santini G Chisesi T Leoni P Coser P Salvagno L Porcellini A Contu A Sertoli MR Centurioni R Guarnaccia C Tedeschi L Congiu M Rizzoli V Italian Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG) trials for diffuse, intermediate and high grade NHl [abstract] Blood 1995 440a 17"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0054|cit54","unstructured":"Santini G Chisesi T Leoni P Coser P Salvagno L Porcellini A Contu A Sertoli MR Olivieri A Centurioni R Guarnaccia C Tedeschi L Congiu A Rizzoli V Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG) trials for diffuse, intermediate and high grade NHL [abstract] Bone Marrow Transplantation 1996 S31 43"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0057|cit55","unstructured":"Santini G Salvagno L VACOP-B vs VACOP-B + autologous BM transplantation (ABMT) for aggressive non-Hodgkin's lymphoma. A study of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG) [abstract] Bone Marrow Transplantation 1997 S154 5364"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0055|cit56","unstructured":"Santini G Salvagno L Leoni P Chisesi T Congiu AM Rizzoli V VACOP-B vs VACOP-B plus ABMT for aggressive non-hodgkin's lymphoma (NHL). Results of a prospective randomised trial [abstract] Blood 1998 465a 10"},{"issue":"8","key":"10.1002\/14651858.CD004024.pub2-BIB0056|cit57","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.1998.16.8.2796","article-title":"VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group","volume":"16","author":"Santini","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdi399","article-title":"Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin\u00b4s lymphoma: long-term resulsts by the NHLCSG","volume":"16","author":"Olivieri","year":"2005","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0059|cit59","unstructured":"Santini G Congiu A Olivieri A Maiolino I Chisesi T Salvagno L Vacop-B vs Vacop-B + high-dose sequential therapy (HDS) for aggressive non-Hodgkin's lymphoma (NHL) Bone Marrow Transplantation 2002 S8-9 (abstract O110)"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0060|cit60","unstructured":"Santini G Congiu A Rubagotti A Sertoli MR Olivieri A Majolino I Chisesi T Salvagno L Quaini R Centurioni R Contu A Candela M Rizzoli V VACOP-B vs VACOP-B high dose sequential therapy (HDS) for aggressive non-Hodgkin's lymphoma (NHL) - a report of the Non-Hodgkin's Lymphoma Co-operative Study Group [abstract] 2002 277 44"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0061|cit61","unstructured":"Santini G Olivieri A Majolino I Chisesi T Salvagno L Biglio A De Souza CA Congiu M Rizzoli V VACOP-B vs VACOP-B plus high-dose sequential therapy (HDS) for aggressive non-hodgkin's lymphoma (NHL) [abstract] Blood 2001 862a 11"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0062|cit62","unstructured":"Santini G Olivieri A Majolino I Congiu A Chisesi T De Souza C VACOP-B vs VACOP-B + high-dose sequential therapy (HDS) for aggressive non-Hodgkin's lymphoma (NHL). Final analysis of the NHLCSG [abstract] 29th Annual Meeting of the European Group for Blood and Marrow Transplantation March 2003"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0063|cit63","unstructured":"Santini G Olivieri A Majolino I Congiu A Chisesi T De Souza C VACOP-B vs VACOP-B High-dose sequential therapy (HDS) for aggressive non-Hodgkin's lymphoma (NHL). Final analysis of the NHLCSG [abstract] 8th Congress of the European Haematology Association (EHA) Lyon, France June 2003"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0064|cit64","unstructured":"Santini G Olivieri A Majolino I Congiu A Chisesi T Salvagno L Quaini R Rubagotti A Centurioni R Contu A Candela M Rizzoli V VACOP-B vs VACOP-B + high dose sequential therapy (HDS) for aggressive non-Hodgkin's lymphoma (NHL) [abstract] Annals of Oncology 2002 75 24"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0065|cit65","unstructured":"Sertoli MR NHL Cooperative Study Group VACOP-B vs VACOP-B + high dose sequential therapy (HDS) for diffuse non Hodgkin's lymphoma. Final analysis of the NHL Cooperative Study Group (NHLCSG) Proceedings of the American Society of Clinical Oncology 2003 564 10883"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0066|cit66","unstructured":"Hagenbeek A Verdonck L Sonneveld P Schouten HC van Imhoff G van Putten W Dutch HOVON Group CHOP chemotherapy versus autologous bone marrow transplantation in slowly responding patients with intermediate and high grade malignant non-Hodgkin's lymphoma. Results from a prospective randomized phase III clinical trial in 294 patients [abstract] Blood 1993 332a 33"},{"issue":"3","key":"10.1002\/14651858.CD004024.pub2-BIB0067|cit67","first-page":"463","article-title":"Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL)","volume":"16","author":"Uyl-de Groot","year":"1995","journal-title":"Bone Marrow Transplantation"},{"issue":"16","key":"10.1002\/14651858.CD004024.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJM199504203321601","article-title":"Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma","volume":"332","author":"Verdonck","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0069|cit69","unstructured":"Vitolo U Liberati AM Lambertenghi Deliliers G Calvi R Baldini L Bertini M Brugiatelli M Cabras MG Di Renzo N Federico M Freilone R Parvis G Pavone V Petrini M Salvi F Sborgia M Todeschini G Trottini M Gallo E Italian Lymphoma Intergroup (ILI) A multicenter randomized trial by Italian Lymphoma Intergroup (ILI) comparing high dose chemotherapy (HDS) with autologous stem cell transplantation (ASCT) vs intensfied chemotherapy MegaCEOP in high risk diffuse large cell lymphoma (DLCL): no difference in outcome and toxicity [abstract] Blood 2001 252b 13"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0070|cit70","unstructured":"Vitolo U Liberati AM Lambertenghi Deliliers G Calvi R Baldini L Bertini M Brugiatelli M Cabras MG Di Renzo N Federico M Freilone R Parvis G Pavone V Petrini M Salvi F Sborgia M Todeschini G Trottini M Gallo E Italian Lymphoma Intergroup (ILI) A multicenter randomized trial by Italian Lymphoma Intergroup (ILI) comparing high dose chemotherapy (HDS) with autologous stem cell transplantation (ASCT) vs intensfied chemotherapy MegaCEOP in high risk diffuse large cell lymphoma (DLCL): no difference in outcome and toxicity [abstract] Blood 2001 725a 726a 14"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0071|cit71","unstructured":"Vitolo U Liberati AM Lambertenghi Deliliers G Calvi R Baldini L Bertini M High dose chemotherapy (HDS) with autologous stem cell transplantation (ASCT) vs intensified chemotherapy MegaCEOP in high risk diffuse large cell lymphoma (DLCL): An update of a multicenter randomized trial by Italian Lymphoma Intergroup (ILI) Annals of oncology Lugano Oxford University Press 2002 29 (abstract 086)"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0072|cit72","unstructured":"Vitolo U Liberati AM Lambertenghi Deliliers G Calvi R Bertini M Freilone R Baldini L Brugiatelli M Di Renzo N Federico M Cabras MG Parvis G Pavone V Petrini M Salvi F Sborgia M Todeschini G Gallo E Italian Lymphoma Intergroup (ILI) High dose sequential chemotherapy (HDS) with autologous transplantation (ASCT) vs intensified chemotherapy MegaCEOP in poor prognosis diffuse large cell lymphoma (DLCL): comparable remission rate and toxicity in a multicenter randomized trial [abstract] Blood 2000 792a 12"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0074|cit73","unstructured":"Linch DC Yung L Smith P Maclennan K Jack A Hancock B A randomised trial of CHOP x 6-8 vs CHOP x 3 + BEAM + ASCT in 457 patients with poor prognosis histologically aggressive non-Hodgkins lymphoma Annals of Oncology Lugano Oxford University Press 2002 28 (abstract 085)"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0073|cit74","unstructured":"Linch DC Yung L Smith P Maclennan K Jack A Hancock B A randomised trial of CHOP x 6-8 vs CHOP x 3 + BEAM + ASCT in 457 patients with poor prognosis histologically aggressive non-Hodgkins lymphoma British Journal of Cancer Cancer Research UK 2002 S1 (abstract CT4)"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0075|cit75","unstructured":"Santini G Sweetenham JW Simnett S Guelfi M Bruzzi P Parmar M Qian W Nagler A Holte H Goldstone AH Autologous stem cell transplantation (ASCT) in first remission improves outcome in adult patients (pts) with lymphoblastic lymphoma (LBL): results from a randomized trial of the European Group for Blood and Marrow Transplantation (EBMT) and the UK Lymphoma Group (UKLG) [abstract] Bone Marrow Transplantation 1998 S180 5184"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0080|cit76","unstructured":"Sweetenham JW Santini G Adult lymphoblastic lymphoma (LBL): preliminary results from the EBMT\/UKLG randomised trial of conventional dose versus standard dose post remission therapy & an analysis of prognostic factors [abstract] Bone Marrow Transplantation 1997 S153 3893"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0076|cit77","unstructured":"Sweetenham JW Santini G Gibson D Guelfi M Simnett SJ Machin D Conventional dose consolidation\/maintenance versus high dose therapy and autologous stem cell transplantation for adult patients (pts) with lymphoblastic lymphoma (LGL) in first remission: a progress report on the ABMT\/UKLG randomised trial [abstract] Annals of Oncology 1996 177 4096"},{"issue":"11","key":"10.1002\/14651858.CD004024.pub2-BIB0077|cit78","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2001.19.11.2927","article-title":"High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation\/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group","volume":"19","author":"Sweetenham","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0078|cit79","unstructured":"Sweetenham JW Santini G Simnett S Bruzzi P Nagler A Holte H Goldstone AH Autologous stem cell transplantation (ASCT) in first remission improves relapse free survival (RFS) in adult patients (pts) with lymphoblastic lymphoma (LBL): Results from a randomised trial of the European Group for Blood and Marrow Transplantation (EBMT) and the UK Lymphoma Group (UKLG) [abstract] Proceedings of the American Society of Clinical Oncology 1998 17a 46"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0079|cit80","unstructured":"Sweetenham JW Santini G Simnett S Gibson D Guelfi M Bruzzi P Machin D Goldstone AH Conventional dose versus high dose post-remission therapy for adults with lymphoblastic lymphoma - a progress report on the EBMT\/UKLG trial and a preliminary analysis of prognostic factors [abstract] Blood 1996 124a 18"},{"issue":"6","key":"10.1002\/14651858.CD004024.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.thj.6200323","article-title":"A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma.","volume":"4","author":"Agthoven van","year":"2003","journal-title":"Hematology Journal"},{"issue":"5","key":"10.1002\/14651858.CD004024.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/sim.4780060505","article-title":"Issues of efficiency in combining proportions of deaths from several clinical trials.","volume":"6","author":"Buyse","year":"1987","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1200\/JCO.1989.7.8.1018","article-title":"LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma.","volume":"7","author":"Coiffier","year":"1989","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004024.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).","volume":"1","author":"Coiffier","year":"1990","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0085|cit85","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1002\/14651858.CD004024.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.1994.12.4.769","article-title":"Randomised comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.","volume":"12","author":"Cooper","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD004024.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1008338607231","article-title":"Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI).","volume":"10","author":"Cortelazzo","year":"1999","journal-title":"Annals of Oncology"},{"issue":"6964","key":"10.1002\/14651858.CD004024.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD004024.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0197-2456(01)00152-0","article-title":"Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer","volume":"22","author":"Duchateau","year":"2001","journal-title":"Controlled Clinical Trials"},{"issue":"7124","key":"10.1002\/14651858.CD004024.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","article-title":"Bias in location and selection of studies","volume":"316","author":"Egger","year":"1998","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD004024.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bmt.1701081","article-title":"Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index.","volume":"21","author":"Fanin","year":"1998","journal-title":"Bone Marrow Transplantation"},{"issue":"14","key":"10.1002\/14651858.CD004024.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD004024.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/1097-0142(19941101)74:9+<2657::AID-CNCR2820741812>3.0.CO;2-T","article-title":"Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years.","volume":"74","author":"Fisher","year":"1994","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD004024.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1200\/JCO.1993.11.5.931","article-title":"Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study","volume":"11","author":"Freedman","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD004024.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/sj.bmt.1702012","article-title":"The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses.","volume":"24","author":"Frei","year":"1999","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004024.pub2-BIB0097|cit97","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"issue":"11-12","key":"10.1002\/14651858.CD004024.pub2-BIB0098|cit98","first-page":"1727","article-title":"A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.","volume":"63","author":"Goldie","year":"1979","journal-title":"Cancer Treatment Reports"},{"issue":"19","key":"10.1002\/14651858.CD004024.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199211053271903","article-title":"Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma","volume":"327","author":"Gordon","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD004024.pub2-BIB0100|cit100","first-page":"3024","article-title":"Chemotherapy of malignant lymphoma with adriamycin","volume":"33","author":"Gottlieb","year":"1973","journal-title":"Cancer Research"},{"issue":"6","key":"10.1002\/14651858.CD004024.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1083-8791(01)80003-3","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review.","volume":"7","author":"Hahn","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1002\/14651858.CD004024.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.bbmt.2003.09.012","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma.","volume":"9","author":"Hahn","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1002\/14651858.CD004024.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1182\/blood.V88.11.4085.bloodjournal88114085","article-title":"Lymphoma classification--the gap between biology and clinical management is closing","volume":"88","author":"Hiddemann","year":"1996","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"670\u20134","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"British Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD004024.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3816\/CLM.2003.n.014","article-title":"Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.","volume":"4","author":"Intragumtornchai","year":"2003","journal-title":"Clinical Lymphoma"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2000.02244.x","article-title":"A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one half of patients significantly mobilize malignant cells.","volume":"110","author":"Jacquy","year":"2000","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1002\/14651858.CD004024.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jama.1995.03530100070037","article-title":"A comparison of meta-analytic results using literature vs individual patient data. Paternal cell immunization for recurrent miscarriage","volume":"274","author":"Jeng","year":"1995","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD004024.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V96.7.2399","article-title":"High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.","volume":"96","author":"Kewalramani","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD004024.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V72.2.436.436","article-title":"The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype.","volume":"72","author":"Lippman","year":"1988","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD004024.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","article-title":"Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma","volume":"38","author":"McKelvey","year":"1976","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD004024.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood.V89.12.4514","article-title":"Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma.","volume":"89","author":"Melnyk","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD004024.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"Jounral of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004024.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0197-2456(94)00031-W","article-title":"Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists","volume":"16","author":"Moher","year":"1995","journal-title":"Controlled Clinical Trials"},{"issue":"9128","key":"10.1002\/14651858.CD004024.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD004024.pub2-BIB0116|cit116","first-page":"3687","article-title":"Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).","volume":"95","author":"Mounier","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD004024.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood.V80.5.1130.1130","article-title":"High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study","volume":"80","author":"Nademanee","year":"1992","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD004024.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1182\/blood.V90.10.3844","article-title":"Results of high-dose therapy and autologous bone marrow\/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group","volume":"90","author":"Nademanee","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0119|cit119","first-page":"53","article-title":"Mathematical interpretation of tumor growth kinetics","volume-title":"Clinical interpretation and practice of cancer chemotherapy","volume":"N\/A","author":"Norton","year":"1982"},{"issue":"1","key":"10.1002\/14651858.CD004024.pub2-BIB0120|cit120","first-page":"163","article-title":"The Norton-Simon hypothesis revisited","volume":"70","author":"Norton","year":"1986","journal-title":"Cancer Treatment Reports"},{"issue":"24","key":"10.1002\/14651858.CD004024.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004024.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD004024.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"23","key":"10.1002\/14651858.CD004024.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD004024.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.","volume":"329","author":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004024.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ije\/31.1.150","article-title":"Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed","volume":"31","author":"Robinson","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD004024.pub2-BIB0127|cit127","first-page":"935","article-title":"End points in cancer clinical trials and the drug approval process.","volume":"8","author":"Schilsky","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1002\/14651858.CD004024.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.1999.17.1.423","article-title":"International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.","volume":"17","author":"Shipp","year":"1999","journal-title":"Jounral of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD004024.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.1365-2257.2000.00270.x","article-title":"Autologous stem cell transplantation for malignancy: a systematic review of the literature","volume":"22","author":"Simnett","year":"2000","journal-title":"Clinical and Laboratory Haematology"},{"issue":"8842","key":"10.1002\/14651858.CD004024.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0140-6736(93)93004-K","article-title":"Meta-analysis of the literature or of individual patient data: is there a difference?","volume":"341","author":"Stewart","year":"1993","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD004024.pub2-BIB0131|cit131","first-page":"1304","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis","volume":"88","author":"Strehl","year":"2003","journal-title":"Haematologica"},{"issue":"13","key":"10.1002\/14651858.CD004024.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD004024.pub2-BIB0133|cit133","first-page":"463","article-title":"Cost-effectiveness of ASCT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).","volume":"16","author":"Uyl-de Groot","year":"1995","journal-title":"Bone Marrow Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD004024.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","article-title":"The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus","volume":"51","author":"Verhagen","year":"1998","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD004024.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1997.15.2.491","article-title":"Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high risk diffuse large-cell lymphoma","volume":"15","author":"Vitolo","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD004024.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004024.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:44:08Z","timestamp":1777459448000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004024.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":136,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004024.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,23]]}}}